SKSarah Klein

Sarah Klein

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sarah Klein has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Adriana Sliwa-Primorac

    Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, ETH Zurich 1 , Zurich 8093 , Switzerland

    1 shared publication
  • Alistair R. R. Forrest

    Harry Perkins Institute of Medical Research, QEII Medical Centre and Centre for Medical Research, The University of Western Australia, Nedlands, Perth, WA 6009, Australia

    1 shared publication
  • Anthony Mathelier

    Centre for Molecular Medicine and Therapeutics, Child and Family Research Institute 2 , Department of Medical Genetics Vancouver, British Columbia , Canada V5Z 4H4

    1 shared publication
  • Carsten O. Daub

    RIKEN Center for Life Science Technologies 4 , Division of Genomic Technologies, Yokohama, Kanagawa 230-0045 , Japan

    1 shared publication
  • Chloé Chong

    Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, ETH Zurich 1 , Zurich 8093 , Switzerland

    1 shared publication
  • Erik Arner

    RIKEN Center for Life Science Technologies 4 , Division of Genomic Technologies, Yokohama, Kanagawa 230-0045 , Japan

    1 shared publication

Latest Publications

  • Open Access

    DeepCAGE transcriptomics identify HOXD10 as a transcription factor regulating lymphatic endothelial responses to VEGF-C

    by Sarah Klein, Lothar C. Dieterich, Anthony Mathelier, Chloé Chong, Adriana Sliwa-Primorac, Young-Kwon Hong, Jay W. Shin, Marina Lizio, Masayoshi Itoh, Hideya Kawaji, et al.

    Lymphangiogenesis plays a crucial role during development, in cancer metastasis and in inflammation. Activation of VEGFR-3 (also known as FLT4) by VEGF-C is one of the main drivers of lymphangiogenesis, but the transcriptional events downstream of VEGFR-3 activation are largely unknown. Recently, we identified a wave of immediate early transcription factors that are upregulated in human lymphatic endothelial cells (LECs) within the first 30 to 80 min after VEGFR-3 activation. Expression of these transcription factors must be regulated by additional pre-existing transcription factors that are rapidly activated by VEGFR-3 signaling. Using transcription factor activity analysis, we identified the homeobox transcription factor HOXD10 to be specifically activated at early time points after VEGFR-3 stimulation, and to regulate expression of immediate early transcription factors, including NR4A1. Gain- and loss-of-function studies revealed that HOXD10 is involved in LECs migration and formation of cord-like structures. Furthermore, HOXD10 regulates expression of VE-cadherin, claudin-5 and NOS3 (also known as e-NOS), and promotes lymphatic endothelial permeability. Taken together, these results reveal an important and unanticipated role of HOXD10 in the regulation of VEGFR-3 signaling in lymphatic endothelial cells, and in the control of lymphangiogenesis and permeability.